Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate
Status:
Completed
Trial end date:
2020-07-02
Target enrollment:
Participant gender:
Summary
Subjects are asked to take part in a clinical research study that tests Eribulin, a new drug.
Eribulin is an investigational (experimental) anti-cancer agent that has not been approved by
the Food and Drug Administration (FDA) for use in patients with brain metastases. Eribulin is
FDA approved for use in patients with metastatic breast cancer but the effect it may or may
not have on brain metastases has not been studied.